Roche Expects Better Xofluza Sales After New Indication
Executive Summary
Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.
You may also be interested in...
Roche's Xofluza Reduces Flu Symptoms In Children
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
VBI Is Ready To Take On HBV Vaccine Market
VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax.
Apellis Comes Closer To Taking On Alexion In PNH
Besting Alexion’s Soliris in a head-to-head Phase III trial portends a place in the market for Apellis’ competitor in paroxysmal nocturnal hemoglobinuria. But challenges dog both companies.